Categories

Category: Health Tech

Big Health’s CEO: Working With Big Healthcare (CVS) & Big Pharma (as a DTx) on Mental Health

By JESSICA DaMASSA, WTF HEALTH

Big Health bills itself as a “complete 24-hour solution for mental health,” offering Sleepio to those who have trouble sleeping and Daylight to those who suffer from worry and anxiety during the day. Fresh off a $39M Series B in June 2020 (total $54.3M) — and having just landed Daylight onto CVS Health’s digital health formulary to join Sleepio there as a “point solution” payors can easily integrate into their benefits offerings — co-founder & CEO Peter Hames stops by for an ENORMOUS conversation about the ‘state-of-play’ for digital mental health companies like his own. Has CVS Health’s digital formulary made it any easier to contract with employers and get the attention of health consumers? And, what of the attention being paid to Big Health itself? As we hit “peak platformization” in digital health, is the company a prime acquisition target? (Note: Omada Health’s CEO Sean Duffy is a friend and investor and we get a good laugh around the 15-minute mark when we fact-check some rumors… ) Finally, another “insight highlight” worth mentioning: some candid conversation on what’s happening in digital therapeutics (DTx) as Peter is the Chair of the category’s industry org, the Digital Therapeutics Alliance. Does Big Pharma still have an appetite for DTx despite some rough news about partnerships with startups in recent months? You’ll want to tune in around 17:30 for more on that too.

Health in 2 Point 00, Episode 148 | A colonoscopy story (& other health tech news)

Today on Health in 2 Point 00, Jess might be a little wary of my colonoscopy story, but it reveals just how well insurance companies communicate. In this episode, Jess and I cover GoodRx filing an S1 to go public, Trellus Health raising $5 million in seed funding for its platform for inflammatory bowel disease (IBD) and other chronic conditions, Klara Health raising $15 million for patient engagement, and Castor raising $12 million for its clinical trial platform. —Matthew Holt

Announcing The COVID-19 Symptom Data Challenge

By FARZAD MOSTASHARI

In Partnership with the Duke-Margolis Center for Health Policy, Resolve to Save Lives, Carnegie Mellon University, and University of Maryland, Catalyst @ Health 2.0 is excited to announce the launch of The COVID-19 Symptom Data Challenge. The COVID-19 Symptom Data Challenge is looking for novel analytic approaches that use COVID-19 Symptom Survey data to enable earlier detection and improved situational awareness of the outbreak by public health and the public. 

How the Challenge Works:

In Phase I, innovators submit a white paper (“digital poster”) summarizing the approach, methods, analysis, findings, relevant figures and graphs of their analytic approach using Symptom Survey public data (see challenge submission criteria for more). Judges will evaluate the entries based on Validity, Scientific Rigor, Impact, and User Experience and award five semi-finalists $5,000 each. Semi-finalists will present their analytic approaches to a judging panel and three semi-finalists will be selected to advance to Phase II. The semi-finalists will develop a prototype (simulation or visualization) using their analytic approach and present their prototype at a virtual unveiling event. Judges will select a grand prize winner and the runner up (2nd place). The grand prize winner will be awarded $50,000 and the runner up will be awarded $25,000.The winning analytic design will be featured on the Facebook Data For Good website and the winning team will have the opportunity to participate in a discussion forum with representatives from public health agencies. 

Phase I applications for the challenge are due Tuesday, September 29th, 2020 11:59:59 PM ET.

Learn more about the COVID-19 Symptom Data Challenge HERE.

Challenge participants will leverage aggregated data from the COVID-19 symptom surveys conducted by Carnegie Mellon University and the University of Maryland, in partnership with Facebook Data for Good. Approaches can integrate publicly available anonymized datasets to validate and extend predictive utility of symptom data and should assess the impact of the integration of symptom data on identifying inflection points in state, local, or regional COVID outbreaks as well guiding individual and policy decision-making. 

These are the largest and most detailed surveys ever conducted during a public health emergency, with over 25M responses recorded to date, across 200+ countries and territories and 55+ languages. Challenge partners look forward to seeing participant’s proposed approaches leveraging this data, as well as welcome feedback on the data’s usefulness in modeling efforts. 

Indu Subaiya, co-founder of Catalyst @ Health 2.0 (“Catalyst”) met with Farzad Mostashari, Challenge Chair, to discuss the launch of the COVID-19 Symptom Data Challenge. Indu and Farzad walked through the movement around open data as it relates to the COVID-19 pandemic, as well as the challenge goals, partners, evaluation criteria, and prizes.

Continue reading…

Health in 2 Point 00, Episode 147 | The Most Confusing Episode So Far

With 3 consecutive days of $100M in funding, here is the most confusing (or rather the most confused we have been) Episode 147 of Health in 2 Point 00. Jess asks me about Verily partnering with Swiss Re to get into the stop-loss insurance game, Prescryptive Health raising a $26M Series A for their maybe GoodRx-like or PBM platform, Sonde Health acquiring NeuroLex for its vocal biomarkers platform, Aetion reopening their Series B and raising another $19M to the $36M they have already raised, and Otsuka after investing millions of dollars in Proteus, deciding to buy the rest of it with $15M, but we don’t know why any of these deals happenedMatthew Holt

Continue reading…

COVID-19 is Bringing Data Privacy into the Spotlight – This is How Healthcare Companies Should Respond

By DAN LINTON

Privacy concerns across the country continue to increase, and consumers expect their healthcare information to be private. Headline-making data sales, skepticism of Silicon Valley privacy practices, and COVID-19 contact tracing concerns compounded with a general lack of consumer awareness have continued to generate an ongoing storm ofnegative press and political scrutiny.

With COVID-19 continuing to rampage throughout the country, there is a need for the contact tracing and other technology applications to assess public health. At the same time, changing HHS rules are giving Americans more access and control over their own health data. Both availability and the promise of positive impact of data on people’s lives has never been greater.

Despite the critical need and incredible potential, there is still a great deal of confusion, lack of awareness and heightened concern among consumers. Studies show that the vast majority of Americans think the potential risks of data collection outweighs the potential benefits.

Clamping down on data privacy stifles innovation, and moving forward as we’ve been doing presents a potential privacy minefield. So, what should the healthcare industry do about it?

Continue reading…

THCB Gang Episode 23 8/27

Episode 23 of “The THCB Gang” was live-streamed on Thursday, August 27th! Watch it below!

Matthew Holt (@boltyboy) was joined by some of our regulars: health futurist Ian Morrison (@seccurve), WTF Health Host Jessica DaMassa (@jessdamassa), health care consultant Daniel O’Neill (@dp_oneill). The conversation revolved around how providers should reshape some of their practices amid the pandemic, what the large Teladoc-Livongo merger brings to the marketplace, and how there are still lots of potential ways start-ups can fit their models into care practices in the industry.

If you’d rather listen to the episode, the audio is preserved as a weekly podcast available on our iTunes & Spotify channels — Zoya Khan

Health in 2 Point 00, Episode 146 | Can We Call it Digital Health Anymore?

Can we call this digital health anymore? What do we call it? On Episode 146 of Health in 2 Point 00, Jessica DaMassa asks me about Amwell filing for their S1, Lyra Health getting $110M to develop their mental health platform, PatientPop raising $50M to improve SEO for doctors and patients (they also brought Johnathan Bush on their board!), Brightline closing $20M for their behavioral health platform for kids, and Science 37 getting $40M for their site-less clinical trialsMatthew Holt

Continue reading…

The Bayer Deal: One Drop’s CEO on New $98M & How Data Science Will Fix Chronic Condition Care

By JESSICA DaMASSA, WTF HEALTH

One Drop just landed a $98.7M deal with Bayer — and we got the details from CEO Jeff Dachis. The timing of this deal is nothing short of impeccable: less than a year after the life sciences giant led One Drop’s Series B with a $40M investment, and amidst a veritable funding frenzy aimed at growing digital health companies focused on chronic condition management. So, how is One Drop planning to use this investment (part Series C/part development fees) to expand their data science platform known for diabetes and hypertension into some of Bayer’s biggest areas of focus — cardiology, oncology, and women’s health? And how does this even-closer relationship with such a consumer health brand help One Drop further evolve the retail side of its go-to-market strategy? Don’t forget — One Drop is sold direct-to-consumer via CVS, Walmart, and Amazon in addition to the more traditional routes via employers and payers. It’s a full breakdown of the deal and a walk through the key points of differentiation Jeff sees as integral to shaping One Drop’s move for greater global market share.

Health in 2 Point 00, Episode 145 | Amwell, OneDrop, Outset Medical & Podimetrics

Today on Health in 2 Point 00, Jess asks me about the big news that Google Cloud has entered into a partnership with Amwell and invested $100 million into the company—looks like their IPO is really a thing! OneDrop gets $98.7 million in a partnership with Bayer, following at $40 million partnership last November, in a funding and development agreement. Outset Medical files their S1 and is going to go public, looking for $100 million for their portable dialysis system, and finally Podimetrics raises another $8 million for their foot ulcer detection platform for diabetics. —Matthew Holt

Change Healthcare’s CEO on Payers, Providers & The New Healthcare Economy

By JESSICA DaMASSA, WTF HEALTH

From his vantage point at the helm of one of healthcare’s biggest IT infrastructure companies, Change Healthcare’s President & CEO, Neil de Crescenzo, has an unrivaled perspective at how covid19 has impacted hospital systems and payers. His business builds the “connective tissue” that not only supports the administrative management and patient engagement aspects of “Big Healthcare,” but it also literally helps those organizations make money, processing about $1.5 Trillion in claims each year. So, what’s he seen so far in 2020? And what’s ahead for 2021? Neil stops by to talk about current challenges facing healthcare provider orgs and payers — and what’s ahead in the “new” healthcare economy where “change” is the only constant. From HHS’s new interoperability rules to telehealth and the more dispersed healthcare system it will inevitably create, we dive into all things future of health including the details behind Change’s two recent health tech acquisitions (each over $200M), what Neil thinks about the Teladoc-Livongo merger, and how digital health startups have an unprecedented opportunity to help expand the healthcare system beyond its traditional footprint.

Registration

Forgotten Password?